Cel-Sci Corporation

CVM Healthcare Biotechnology

EPS
+65.4%
Free cash flow
−2.33%
Total debt
−39.7%

Quarter to June 2026, against a year earlier

1.45 0.08 +5.84%
Market cap
$24.1M
P/E
0.0×
Fwd P/E
−12.2×
Dividend yield
—
F-score
4/9
Altman Z
−1.63
Beneish M
−2.35
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.48 0.60 1.39 2.26
Net Debt/EBITDA
0.59 (0.58) 0.27 1.04
Debt/Equity
0.35 0.64 0.45 0.36
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.33) (0.49) (0.50) (1.15)
Book value per Share
0.90 0.84 1.39 3.93
Free Cash Flow
(4.03) (4.02) (4.02) (4.68)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026